Phase III trial of a non-myeloablative preparative regimen with fludarabine and busulfan with or without anti-lymphocyte antibodies (Campath-1H [alemtuzumab] or ATG [antithymocyte globulin]) for patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation from an HLA compatible donor
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 10 Apr 2011
At a glance
- Drugs Alemtuzumab; Antithymocyte globulin; Busulfan; Ciclosporin; Fludarabine; Methotrexate
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Apr 2011 Status changed from recruiting to withdrawn prior to recruitment, according to ClinicalTrials.gov. The principal investigator no londer works for Hadassah.
- 03 Nov 2005 New trial record.